Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
66.90    -1.10 (-1.62%)
Bid:
66.80
Ask:
67.00
Spread: 0.20 (0.299%)
Market Cap: £591.01m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Director Declaration

12 Feb 2019 09:36

RNS Number : 7578P
IP Group PLC
12 February 2019
 

FOR RELEASE ON

12 February 2019

 

Director Declaration

IP Group plc (LSE: IPO) ("the Group"), the developer of intellectual property-based businesses, confirms pursuant to LR 9.6.14 that David Baynes, an executive director of the Group, has been appointed as a non-executive director of Xeros Technology Group plc with immediate effect.

 

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Angela Leach, Company SecretaryLiz Vaughan-Adams, Communications

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7979 853802

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RDNCKBDNCBKKQBD
Date   Source Headline
19th Oct 20216:31 pmRNSTransaction in Own Shares
19th Oct 20217:00 amRNSTransaction in Own Shares
18th Oct 20217:00 amRNSTransaction in Own Shares
14th Oct 20216:27 pmRNSTransaction in Own Shares
13th Oct 20216:22 pmRNSTransaction in Own Shares
13th Oct 202111:36 amRNSDirector Declaration
13th Oct 20219:03 amRNSHolding(s) in Company
12th Oct 20216:20 pmRNSTransaction in Own Shares
12th Oct 20212:09 pmRNSDirector/PDMR Shareholding
12th Oct 20217:00 amRNSTransaction in Own Shares
11th Oct 20217:41 amRNSTransaction in Own Shares
8th Oct 20217:00 amRNSShare buyback programme
6th Oct 20217:00 amRNSBoard changes
5th Oct 20214:44 pmRNSHolding(s) in Company
30th Sep 20214:11 pmRNSTotal Voting Rights
30th Sep 20217:45 amRNSIP Group generates £84m from Oxford Nanopore IPO
27th Sep 202112:40 pmRNSDirector/PDMR Shareholding
23rd Sep 20213:57 pmRNSFurther re Scrip Dividend
16th Sep 20217:08 amRNSOxford Nanopore confirms ITF; MoU with Oracle
10th Sep 20215:21 pmRNSHolding(s) in Company
8th Sep 202110:53 amRNSDirector/PDMR Shareholding, SAYE scheme
19th Aug 202110:41 amRNSScrip Dividend Reference Price
12th Aug 20215:05 pmRNSDirector Declaration
5th Aug 20217:00 amRNSHalf-yearly results
27th Jul 20217:03 amRNSPortfolio company Artios Pharma raises $153m
22nd Jul 202111:30 amRNSNotice of Results
1st Jul 20217:00 amRNSTotal Voting Rights
28th Jun 20217:30 amRNSDirector/PDMR Shareholding
18th Jun 20219:52 amRNSDirector/PDMR Shareholding
17th Jun 20217:00 amRNSPortfolio company Apollo Therapeutics raises $145m
15th Jun 20218:00 amRNSFurther re Scrip Dividend
9th Jun 202111:29 amRNSResult of AGM
9th Jun 20217:00 amRNSAGM Statement
7th Jun 20217:00 amRNSPortfolio co Iksuda completes $42m financing round
28th May 20213:36 pmRNSDirector/PDMR Shareholding
28th May 202110:00 amRNSJoint venture with China Everbright to launch fund
27th May 20217:00 amRNSPortfolio co Pulmocide completes $92m Series C
26th May 20212:44 pmRNSUpdate on AGM
20th May 202110:01 amRNSScrip Dividend Reference Price
17th May 202112:44 pmRNSAdditional fair value gain of £20m
12th May 202112:08 pmRNSHolding(s) in Company
10th May 202111:15 amRNSInvestor webinars
6th May 20216:13 pmRNSNotice of AGM, Annual Report, Scrip Dividend
6th May 20215:55 pmRNSLTIP & DBSP awards; Director/PDMR shareholding
5th May 20217:00 amRNSPortfolio company Inivata acquired by NeoGenomics
5th May 20217:00 amRNSPortfolio company Kuur acquired by Athenex
4th May 20217:00 amRNSPortfolio company Oxford Nanopore raises £195m
7th Apr 202111:27 amRNSDirector/PDMR Shareholding
31st Mar 20219:15 amRNSHolding(s) in Company
30th Mar 20217:05 amRNSOxford Nanopore announces preparing for IPO in H2

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.